From what 21 stock analysts predict, the share price for Biogen Inc (BIIB) might increase by 34.78% in the next year. This is based on a 12-month average estimation for BIIB. Price targets go from $236.00 to $400.00. The majority of stock analysts believe BIIB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Biogen Inc has a total of 21 Wall St Analyst ratings. There are 15 buy ratings, 6 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Biogen Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
colin bristow UBS | Hold | $250.0 | maintained | Feb 16, 2024 |
elmar kraus DZ BANK AG | Hold | $236.0 | maintained | Feb 15, 2024 |
george farmer Scotiabank | Buy | $275.0 | maintained | Feb 14, 2024 |
ami fadia Needham | Buy | $300.0 | reiterated | Feb 14, 2024 |
brian skorney Robert W. Baird | Buy | $316.0 | rated | Feb 14, 2024 |
matthew harrison Morgan Stanley | Buy | $346.0 | maintained | Feb 14, 2024 |
evan seigerman BMO Capital | Buy | $285.0 | maintained | Feb 14, 2024 |
terence flynn Morgan Stanley | Buy | $346.0 | maintained | Feb 14, 2024 |
marc goodman Leerink Partners | Buy | None | maintained | Feb 13, 2024 |
chris schott J.P. Morgan | Hold | $270.0 | rated | Feb 13, 2024 |
geoff meacham Bank of America Securities | Hold | $280.0 | maintained | Feb 13, 2024 |
salveen richter Goldman Sachs | Buy | $400.0 | maintained | Feb 13, 2024 |
michael yee Jefferies | Buy | $300.0 | maintained | Feb 12, 2024 |
jay olson Oppenheimer | Buy | $295.0 | maintained | Feb 7, 2024 |
laura chico Wedbush | Hold | $245.0 | maintained | Jan 29, 2024 |
mohit bansal Wells Fargo | Buy | $315.0 | maintained | Jan 25, 2024 |
carter gould Barclays | Hold | $255.0 | maintained | Jan 23, 2024 |
thomas shrader BTIG | Hold | None | maintained | Jan 5, 2024 |
brian abrahams RBC Capital | Buy | $379.0 | maintained | Jan 2, 2024 |
eric schmidt fca Cantor Fitzgerald | Buy | $311.0 | maintained | Dec 20, 2023 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
When did it IPO
0
Staff Count
7,570
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—General
CEO
Mr. Christopher A. Viehbacher
Market Cap
$32.14B
In 2023, BIIB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BIIB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
NDAQ-USD
$55.42
CDW-USD
$247.56
DLTR-USD
$145.43
FANG-USD
$179.75
ACGL-USD
$85.82
CSGP-USD
$83.98